XCancer

Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer

Description:

To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.

Sponsor:

University of California, San Francisco

Phase:

Phase 2

Contacts:

Translational Research Team (CONTACT)

cancercto@health.ucsd.edu

(858) 822-5354

Aditya Bagrodia, MD, FACS (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT07733908 - Click here to see study on

ClinicalTrials.gov

flotufolastat

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Inclusion
  • Eligibility for Focal Therapy: Determined to be an appropriate candidate for focal therapy based on clinical evaluation.
  • Risk Profile: Intermediate-risk , organ-confined PCa
  • Diagnosis: Histologically confirmed PCa.
Exclusion
  • Previous Treatment: Prior treatment for PCa, including radiation therapy, chemotherapy, focal therapy, or androgen deprivation therapy.